A5057418532- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Nonmelanoma Skin Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Nail Diseases and Treatments
- Cutaneous lymphoproliferative disorders research
- Autophagy in Disease and Therapy
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- PI3K/AKT/mTOR signaling in cancer
- Infectious Diseases and Mycology
- Pancreatic and Hepatic Oncology Research
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- Chronic Lymphocytic Leukemia Research
- Dermatological diseases and infestations
- Eosinophilic Disorders and Syndromes
- Ear and Head Tumors
- Advanced Breast Cancer Therapies
- Immunotherapy and Immune Responses
- Reconstructive Facial Surgery Techniques
- Phagocytosis and Immune Regulation
- T-cell and Retrovirus Studies
- Click Chemistry and Applications
- CRISPR and Genetic Engineering
Institut Gustave Roussy
2021-2023
Hospices Civils de Lyon
2012-2022
Hôpital Lyon Sud
2012-2022
Université Claude Bernard Lyon 1
2012-2022
Centre de Recherche en Cancérologie de Lyon
2016-2021
Inserm
2016-2021
Centre National de la Recherche Scientifique
2016-2021
Centre Léon Bérard
2016-2021
University of Utah
2018-2020
Huntsman Cancer Institute
2019-2020
Research Article5 September 2016Open Access Source DataTransparent process ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors Geoffrey Richard Cancer Center of Lyon, INSERM U1052, France CNRS UMR 5286, Université de ISPB, Lyon 1, Centre Léon Bérard, Search for more papers by this author Stéphane Dalle Dermatology Unit, Hospices Civils CH Sud, Pierre Bénite Cedex, Marie-Ambre Monet Maud Ligier Amélie Boespflug Roxane M Pommier Arnaud la Fouchardière Department...
Melanoma treatment has been revolutionized with the development of immune-based therapies that offer durable clinical responses in a subset patients. Clinical outcomes after by immunotherapy can be influenced host's immune system. The system is modified age age-related dysfunction.To evaluate if influences outcome and adverse events patients treated for metastatic melanoma.This was single-center cohort analysis melanoma between January 2007 February 2016, Lyon Sud Hospital, France. A total...
Dermoscopy permits the detection of early-stage melanomas but is difficult to learn. It important develop effective teaching methods. Spaced education a methodology within field adaptive learning that uses online tools reinforce long-term retention.To determine whether spaced dermoscopy module improved skills in continuing medical setting and evaluate participant satisfaction.We designed prospective controlled study with 2 sequential cohorts participants enrolled between September 2010 2013,...
It remains unclear whether immune-related adverse events (irAEs) and glucocorticoid use could impact long-term outcomes in patients treated for solid tumors with immune checkpoint inhibitors (ICI). All a single-agent ICI any advanced cancer were included this retrospective unicentric study. The objectives to assess the of grade ≥3 irAEs, interruption immunotherapy on progression-free survival (PFS) overall (OS). In 828-patient cohort, first occurrence irAEs had no significant PFS or OS....
Facial melanoma is difficult to diagnose and dermatoscopic features are often subtle. Dermatoscopic non-melanoma patterns may have a comparable diagnostic value. In this pilot study, facial lesions were collected retrospectively, resulting in case set of 339 melanomas 308 non-melanomas. Lesions evaluated for the prevalence (> 50% lesional surface) 7 features: scales, white follicles, erythema/reticular vessels, reticular and/or curved lines/fingerprints, structureless brown colour, sharp...
Background: ICIs have dramatically improved patient outcomes in different malignancies. However, the impact of liver metastases (LM) and number metastatic sites (MS) remains unclear patients treated with single-agent anti-PD(L)1. Methods: We aimed to assess prognostic LM MS on progression-free survival (PFS) overall (OS) a large single-arm retrospective multicentric cohort (IMMUCARE) anti-PD(L)-1 for solid tumors. Results: A total 759 were enrolled from January 2012 October 2018. The primary...
Abstract Background Cytotoxic chemotherapy (CC) is currently used in metastatic melanoma after patients have developed resistance to immune checkpoint inhibitors (ICI) and/or Mitogen‐Activated Protein Kinase (MAPKi). We sought evaluate if a previous treatment by ICI or MAPKi influences clinical outcomes treated CC melanoma. Methods Eighty‐eight with melanoma, between January 2009 and October 2019, were retrospectively analyzed. Progression‐Free‐Survival (PFS), Overall Survival (OS), Response...
Abstract Background Patients treated with vemurafenib for metastatic melanoma often develop skin lesions similar to those observed after exposure dioxin‐like compounds. We previously called these MADISH (metabolizing acquired dioxin‐induced hamartoma) when analysing a case of acute dioxin poisoning. Objective performed clinical trial aimed at comparing the under treatment in order bring light possible crosstalk between and pathways. Methods In this series study, we explored histological...